- Home
- OUST vs XNCR Comparison
OUST vs XNCR Comparison
Compare OUST & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- XNCR
- Stock Information
- Founded
- OUST 2015
- XNCR 1997
- Country
- OUST United States
- XNCR United States
- Employees
- OUST N/A
- XNCR N/A
- Industry
- OUST Industrial Machinery/Components
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- OUST Technology
- XNCR Health Care
- Exchange
- OUST Nasdaq
- XNCR Nasdaq
- Market Cap
- OUST 1.1B
- XNCR 1.1B
- IPO Year
- OUST N/A
- XNCR 2013
- Fundamental
- Price
- OUST $31.45
- XNCR $13.86
- Analyst Decision
- OUST Strong Buy
- XNCR Buy
- Analyst Count
- OUST 6
- XNCR 11
- Target Price
- OUST $23.83
- XNCR $24.20
- AVG Volume (30 Days)
- OUST 2.9M
- XNCR 1.5M
- Earning Date
- OUST 11-04-2025
- XNCR 11-06-2025
- Dividend Yield
- OUST N/A
- XNCR N/A
- EPS Growth
- OUST N/A
- XNCR N/A
- EPS
- OUST N/A
- XNCR N/A
- Revenue
- OUST $125,848,000.00
- XNCR $146,929,000.00
- Revenue This Year
- OUST $33.30
- XNCR $22.09
- Revenue Next Year
- OUST $36.50
- XNCR N/A
- P/E Ratio
- OUST N/A
- XNCR N/A
- Revenue Growth
- OUST 26.37
- XNCR N/A
- 52 Week Low
- OUST $6.34
- XNCR $6.92
- 52 Week High
- OUST $41.65
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- OUST 49.41
- XNCR 55.63
- Support Level
- OUST $32.65
- XNCR $12.17
- Resistance Level
- OUST $40.06
- XNCR $15.50
- Average True Range (ATR)
- OUST 3.36
- XNCR 1.15
- MACD
- OUST -0.11
- XNCR -0.12
- Stochastic Oscillator
- OUST 28.21
- XNCR 49.86
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.